RxDoctor Payments Data

Rana Kayali, MD

Internal Medicine · Little Rock, ARNPI 1720041577

Payments from drug & device makers

$550in general payments, 2019–2025

Across 20 payments — averaging $27.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$194
  • Johnson & Johnson$79
  • Pfizer$53
  • Baxter Healthcare$41
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$30
  • Boehringer Ingelheim$25
  • plus $128 from 8 others

What the payments were for

  • Food & beverage$550100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$550 in reported general payments places this provider in the 65th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$143,221
Medicare patients
359
Services billed
1,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$49,243
JardianceEmpagliflozin18$14,637
FarxigaDapagliflozin Propanediol22$12,541
EntrestoSacubitril/Valsartan21$11,363
SymbicortBudesonide/Formoterol Fumarate12$2,642
Potassium Chloride167$1,675
Pantoprazole Sodium113$1,296
Bumetanide83$1,269
Midodrine Hcl15$1,027
CholestyramineCholestyramine (With Sugar)14$990
Metoprolol Succinate112$955
Ventolin HfaAlbuterol Sulfate15$932
Sucralfate33$833
Gabapentin51$780
Albuterol Sulfate HfaAlbuterol Sulfate22$702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$49,24375 claims
AstraZenecaFarxiga, Symbicort$23$15,18434 claims
Boehringer IngelheimJardiance$25$14,63718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →